Final report: Together, we’ve given millions of children a future free of meningitis. Thank you.After more than a decade of breakthrough work, the Meningitis Vaccine Project (MVP) has reached a final milestone. In December, we transitioned our efforts to our global, country, and local partners and closed our doors. With this shift to local ownership—a longstanding goal—our colleagues will carry our efforts forward, helping the powerful MenAfriVac® vaccine continue to reach families throughout sub-Saharan Africa.
Your support has helped us protect millions of lives, given the world a bold new model for vaccine development, and demonstrated that our shared dedication can change the future for women and children worldwide.
It’s been an exhilarating journey. As MVP’s dedicated supporters, you’ve seen how a unique partnership allowed PATH, the World Health Organization, the Serum Institute of India Ltd., and others around the world to create a safe, effective, and affordable vaccine for meningitis A—in record time and at one-tenth the usual cost of developing a vaccine. You’ve followed along as we’ve conducted the clinical trials that ensure the vaccine’s safety and effectiveness. And you’ve stood with us as we’ve brought it to more communities than many thought possible.
As of this month, the vaccine has reached a staggering 200 million people in 15 countries, with campaigns continuing. And to date, not a single vaccinated person has gotten meningitis.
Together, we’ve stopped a devastating killer in its tracks, freeing millions of people from fear, giving children a new chance to thrive, and transforming global health forever. Thank you!
Want to continue your lifesaving role?
The MVP has closed, but PATH’s innovative work to end health inequity and protect the lives of women and children continues in more than 70 countries—and we need your support. Right now, for example, we’re working to stamp out a disease called Japanese encephalitis (JE) that kills or disables thousands of children every year. To learn more and help us bring a safe, effective vaccine to thousands of vulnerable children, visit our JE project on GlobalGiving.
Or visit PATH’s website at www.path.org to learn how we’re accelerating health solutions worldwide.
The Meningitis Vaccine Project is a partnership between PATH and the World Health Organization. Started in 2001 with funding from the Bill & Melinda Gates Foundation, the mission of MVP is to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines. MenAfriVac is a registered trademark of Serum Institute of India Ltd.
The Meningitis Vaccine Project (MVP) continues to help expand the reach of the MenAfriVac® vaccine, freeing millions of Africans from the fear of deadly and debilitating meningitis A.
More than 50 million people are expected to receive one dose of MenAfriVac between October and December of this year, bringing the total number of people vaccinated to more than 200 million since the vaccine launched in 2010.
In October, vaccine rollouts continued in Ethiopia, Mauritania, and Nigeria. This month, Togo will launch the vaccine, followed by Côte d’Ivoire in December. Leaders in Guinea, where meningitis still threatens communities, are eager to introduce the vaccine but have had to postpone efforts as the country battles the Ebola virus. South Sudan, burdened by a tense political situation, has also postponed a campaign. Together, these challenges serve as a poignant reminder of the complex work of global health—and the perseverance necessary to save lives.
As always, MVP also supported regulation, surveillance, epidemic preparedness, and clinical activities this quarter. In addition, the team talked with leaders about how to harness MenAfriVac's proven ability to remain potent for up to four days in temperatures of up to 104°F (40°C) to help the vaccine reach more people. Heat can sap the potency of some vaccines, but MenAfriVac can be transported for short periods without refrigeration. With the right approach to distribution, that flexibility can help it reach remote communities where constant refrigeration isn’t possible.
An important transition at MVP
We would also like to share important news with you, our supporters. With the help of partners worldwide, MVP’s breakthrough efforts have achieved unprecedented wins for health in Africa’s meningitis belt. Now, after nearly 14 years, we are preparing to pass the baton.
MVP will end in December 2014. We are working with partners to ensure that project activities continue sustainably into the future. Please watch for a final update as we draw closer to the end of this year. As always, your support is, and will continue to be, key to our lifesaving efforts. Thank you!
Did you know that MVP is just one example of PATH’s exciting and innovative work to transform the health of women and children worldwide? To learn about our hundreds of projects and get involved, please visit us at www.path.org.
We’re gearing up for an exhilarating fall at the Meningitis Vaccine Project (MVP). An astounding seven countries are preparing to bring the MenAfriVac® vaccine to people across the African continent, protecting them against deadly and debilitating meningitis A. Five of these—Côte d’Ivoire, Guinea, Mauritania, South Sudan, and Togo—will be introducing the vaccine for the first time. In Ethiopia and Nigeria, continued efforts will extend coverage to more communities.
In addition, the global health nonprofit Médecins Sans Frontières (Doctors without Borders) brought the vaccine to more than 19,000 vulnerable refugees in Chad last month.
Together, these efforts are expected to reach a record 55 million more people in 2014—bringing the total number of people vaccinated since 2010 to more than 200 million. What’s more, there still has not been a single case of group A meningitis in anyone who has received the vaccine.
Among other activities, MVP also completed all seven of our MenAfriVac-related clinical trials this quarter. We supported Kenyan and Ugandan leaders to plan 2015 campaigns. And we made important progress toward enabling countries to make MenAfriVac part of their routine immunizations.
Your support, in combination with the dedication of partners worldwide, is key to these lifesaving efforts. Together, we are protecting millions of lives. Thank you!
This quarter, the news is all about heat—and cold—at the Meningitis Vaccine Project (MVP), a collaboration between PATH, the World Health Organization, the Serum Institute of India, Ltd, and partners worldwide.Putting the heat on meningitis A. The lifesaving MenAfriVac® vaccine reached more than 50 million people between the ages of 1 and 29 in 2013, bringing the total number of people protected from deadly and debilitating meningitis A to more than 153 million since 2010. And there still have been no reported cases among people who received the vaccination.Now, we are continuing to expand MenAfriVac’s reach. Special campaigns brought the vaccine to vulnerable refugee communities in Chad and South Sudan in March, and five new countries are preparing for vaccine introduction later this year: Côte d’Ivoire, Guinea, Mauritania, South Sudan, and Togo. Rollouts will also continue in Ethiopia and Nigeria. Together, these efforts are putting the heat on meningitis A—and chasing it out.Taking MenAfriVac out of the cold (chain). Many vaccines must be kept cold during transport, storage, and handling to maintain their efficacy. Maintaining this “cold chain” can be a challenge in hard-to-reach areas without electricity or systems to maintain consistent refrigeration. But in February, a study published in the journal Vaccine demonstrated that with a new distribution approach, MenAfriVac stays effective even if it is transported without constant refrigeration for up to four days at temperatures up to 104°F (40°C). This knowledge could help extend vaccination to even the most remote regions of Africa. A separate study suggested that easing the need for constant refrigeration could cut storage and transportation costs in half.Other MVP achievements include progress on the clinical and regulatory work necessary to allow MenAfriVac to be used among infants and continued support for meningitis surveillance in Africa.Your support has helped make this powerful and wide-reaching work possible. Thank you for joining us as we continue to put the heat on meningitis A—and give people worldwide a new chance to thrive.The Meningitis Vaccine Project is a partnership between PATH and the World Health Organization. Started in 2001 with funding from the Bill & Melinda Gates Foundation, the mission of the MVP is to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines. MenAfriVac® is a registered trademark of Serum Institute of India Ltd.
151 million: That’s the number of people between the age of 1 and 29 years in Africa’s meningitis belt who, as of the end of 2013, no longer have to fear meningitis A. Today, they’re protected by the MenAfriVac® vaccine through the efforts of the Meningitis Vaccine Project, the Serum Institute of India Ltd., and partners worldwide.
151 million: It’s a number so big, it helps to put it into perspective. Picture 94,736 soccer fans at FNB Stadium in Johannesburg, South Africa. Now, picture almost 1,594 more—not just people, but stadiums full of people. Since the vaccine’s launch in 2010, we’ve reached that many children, young people, and adults. And to date, there has not been a single reported case of meningitis A in a vaccinated person—and no reported safety concerns.
In the last quarter of 2013, vaccine introductions in Ethiopia, Nigeria, and The Gambia contributed to this success. In Ethiopia, organizers brought the vaccine to more than 18.6 million people; future efforts will reach an estimated 40 million more. In Nigeria, the third phase of a national campaign reached 21.2 million people, and a fourth phase is planned. Early data from The Gambia suggest that a national campaign reached the entire target population—more than 1.2 million people—in just six days. In Cameroon and Chad, smaller efforts provided vaccines to nomadic, rural, and refugee communities. And as we begin 2014, organizers in Sudan have already made an early start, with a campaign reaching 7.2 million people. As always, these campaigns, and future improvements, are supported by in-depth monitoring and evaluation.
Together, our efforts brought lifesaving protection to more than 48.3 million people in 2013 and prepared us to accomplish even more this year. With your support, and the support of other partners, we’re kicking meningitis out of Africa. Thank you!
The Meningitis Vaccine Project (MVP) is a partnership between PATH and the World Health Organization. Started in 2001 with funding from the Bill & Melinda Gates Foundation, the mission of the MVP is to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines. MenAfriVac® is a registered trademark of Serum Institute of India Ltd.
Project Reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating or by subscribing to this project's RSS feed.
Combined with other sources of funding, this project raised enough money to fund the outlined activities and is no longer accepting donations.
Still want to help?
Support another project run by PATH that needs your help, such as: